Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) today will provide a corporate update and report its financial results for the quarter ended June 30, 2013.
“In the second quarter, we completed a successful IPO, raising approximately $126 million in net proceeds, which will allow us to develop our two late-stage thrombosis programs and a dual Syk-JAK inhibitor for hematologic cancers,” said William Lis, chief executive officer of Portola.
Hey, check out all the research scientist jobs. Post your resume today!
Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) today will provide a corporate update and report its financial results for the quarter ended June 30, 2013.
“In the second quarter, we completed a successful IPO, raising approximately $126 million in net proceeds, which will allow us to develop our two late-stage thrombosis programs and a dual Syk-JAK inhibitor for hematologic cancers,” said William Lis, chief executive officer of Portola.
Hey, check out all the research scientist jobs. Post your resume today!
